SOURCE: NeuroInvestment


March 01, 2010 12:27 ET

ALS Therapeutics Reviewed by NeuroInvestment

CARDIFF, CA--(Marketwire - March 1, 2010) -  NI Research has released the February issue of NeuroInvestment. The issue features a review of ALS, and the search for a genuinely useful treatment for the treatment of this devastating illness. Just as Alzheimer's lyses memory, and schizophrenia dissolves the personality, ALS gradually destroys muscle control, leaving patients almost invariably doomed to death from respiratory failure.

The contents of the February NeuroInvestment include:

  1. ALS programs including those from Amorfix Life Sciences, Cambria Pharmaceuticals, Sangamo Biosciences, CytRx, Trophos, NeuroNova, NeuralStem, Neuraltus, Eisai, and Knopp Neuroscience.
  2. A review of Cambria Pharmaceuticals, focused upon CNS diseases associated with protein misfolding.
  3. Commentary on the FDA rejection of XenoPort/GSK's Horizant
  4. An update on the likely timing of data release for the Medivation Phase III trial for Dimebon
  5. Commentary on the current embrace of self-mutilation as a business strategy for Big Pharma

NeuroInvestment is the independent, monthly review of the neurotherapeutics area. A one-year corporate subscription is $1800, email or hardcopy. Add $250 for dual delivery, add $50 for airmail delivery outside North America. A three month trial subscription is US$600. The February issue is available as a single-issue purchase for US$300.

NI Research is the leading publisher of independent research on the neurotherapeutics industry. NI Research has published NeuroInvestment since 1995; the Private CNS Company Review since 2003; and CNS Disorders/Therapeutics since 2007. NI Research also provides licensing consultation and research for large and small pharmaceutical firms. NI Research has developed an unmatched information base regarding both publicly and privately-held neuro-oriented companies.

Contact Information